As a rapid point-of-care test for Covid-19, our SARS-CoV-2 Antigen Rapid Test is fast and easy to use with high sensitivity. So far by now, it has been listed in the BfArM Antigen Rapid Test List in Germany, the ARTG for legal supply in Australia, and the HSC Common List in the EU. It can also detect main variants of concern, including Omicron, which is already dominant and causes surging cases in the South Africa. With this approval for market entry, Biouhan is now in a position to help boost the fight against the Covid-19 pandemic in the country.
